Safety, Tolerability, and Pharmacokinetics of Lasmiditan When Co-administered With Topiramate in Healthy Subjects

Next Previous
Trial Profile

Safety, Tolerability, and Pharmacokinetics of Lasmiditan When Co-administered With Topiramate in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Lasmiditan (Primary) ; Topiramate (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Eli Lilly

    • Most Recent Events

    • 26 Jan 2018 Status changed from recruiting to completed.
    • 20 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 17 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top